ARTICLE | Distillery Therapeutics
Therapeutics: Peroxisome proliferation activated receptor γ coactivator 1α (PPARGC1A; PGC-1α); nicotinamide adenine dinucleotide (NAD+)
April 21, 2016 7:00 AM UTC
Mouse studies suggest promoting PPARGC1A expression or the NAD+ precursor nicotinamide could help treat acute kidney injury (AKI). In a mouse model of renal ischemia, overexpression of PPARGC1A in the...